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Abstract
Objective—The prehypertension classification was introduced to facilitate prevention efforts
among patients at increased risk for hypertension. Although patients who have been told they have
hypertension report worse outcomes than unaware hypertensives, little is known about whether or
not prehypertension labeling has negative effects. We evaluated the effects of labeling individuals
with prehypertension on blood pressure and health-related quality of life three months later.
Methods—One hundred adults (aged 19 to 82 [mean=40.0] years; 54% women; 64% racial/
ethnic minorities) with screening blood pressure in the prehypertensive range (120-139/80-89 mm
Hg) and no history of diagnosis or treatment of elevated blood pressure were randomly assigned to
either a “Labeled” group in which they were informed of their prehypertension, or an “Unlabeled”
group in which they were not informed. Subjects underwent office blood pressure measurement,
24-hour ambulatory blood pressure monitoring and completed self-report questionnaires at
baseline and three months.
Results—Multilevel mixed effects regression analyses indicated that changes in the white coat
effect, office blood pressure, mean daytime ambulatory blood pressure, and physical and mental
health did not differ significantly between the two groups. Adjusting for age, sex, race/ethnicity
and body mass index did not affect the results.
Conclusion—These findings suggest that labeling patients with prehypertension does not have
negative effects on blood pressure or quality of life. Additional research is needed to develop
approaches to communicating with patients about their blood pressure that will maximize the
clinical and public health impact of the prehypertension classification.
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INTRODUCTION
About one-third of U.S. adults have prehypertension (1), which is associated with an
increased rate of progression to hypertension and increased cardiovascular disease (CVD)
risk compared with normotension (2–6). Prior to the publication of the Seventh Report of the
Joint National Committee on High Blood Pressure (JNC 7; 7), blood pressures (BP) in this
range (120-139/80-89 mm Hg) were classified as “normal” or “high-normal” (8). Though it
is not a disease category, the prehypertension classification was introduced to facilitate early
identification of patients at increased risk for hypertension. Current treatment guidelines
recommend counseling patients with prehypertension on the importance of lifestyle
modification to reduce BP and prevent or delay progression to hypertension; the safety and
efficacy of pharmacologic treatment in this group is the subject of ongoing investigation (9–
13). As the pros and cons of treating BP to lower targets are debated (14), an important
question to address is whether or not labeling patients with prehypertension has unintended
negative consequences that could limit the potential benefits of early identification of
elevated BP.
Observational studies of “hypertension labeling” have demonstrated a broad range of
negative outcomes among patients who are aware of their hypertension status compared
with those who are hypertensive but unaware of the diagnosis. Increases in work
absenteeism (15–18), higher levels of physical symptoms (18,19) and distress (20–23), and
lower health-related quality of life (23–28) have been reported, and are not explained by BP
elevation itself or by drug treatment, suggesting that psychological effects of being labeled
likely play a significant role. Much of the previous work on hypertension labeling has been
limited by observational designs, which leave open a number of alternate interpretations
such as the possibility that health declines or new physical symptoms prompt patients to
seek medical attention and thus increase the opportunity for hypertension to be detected and
diagnosed. The only published experimental studies of hypertension labeling demonstrated
increased office BP among young men who were labeled as hypertensive following
screening compared with those who were not informed of their diagnosis (29,30).
Ambulatory BP monitoring (ABPM) was not performed, so whether or not the increase was
limited to the office setting (i.e., the white coat effect) is unknown. The white coat effect is
defined as a transient increase in BP in the office setting relative to the usual BP, most often
measured as the average daytime ABP (31), and is a source of measurement error that can
affect clinical decision making. In a previous observational study using ABPM, we found
that the white coat effect was larger, on average, among aware versus unaware
hypertensives, and this difference was partly explained by elevated anxiety in the office
setting (32). The white coat effect might be particularly problematic among patients with
prehypertension as it could contribute to the misdiagnosis of hypertension and unnecessary
drug treatments.
The objective of the present study was to evaluate the effects of prehypertension labeling on
the white coat effect and health-related quality of life three months later. One-hundred
subjects, unaware of having elevated BP, were randomly assigned to either a “Labeled”
group in which they were informed of their prehypertension status, or an “Unlabeled” group
in which they (initially) were not informed. We hypothesized that subjects in the Labeled
group would demonstrate greater increases in the white coat effect (i.e., higher office BP
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without changes in average daytime ABP), and greater reductions in health-related quality of
life than those in the Unlabeled group.
METHOD
Study Population
The target study population was healthy adults who were previously unaware of having
elevated BP. Two recruitment strategies were used: (1) referrals from an internal medicine
practice at Columbia University Medical Center (CUMC), and (2) advertisements for free
BP screenings posted around the CUMC complex. Persons who responded to study
advertisements or who were flagged by the physician (S.F.) were screened by a research
assistant to determine eligibility. To avoid any possible labeling effect of participation, the
research assistant described the purpose of the study as examining different ways that
physicians talk to patients about their health; BP measurement was included in the
explanation of procedures but was not the focus.
Screening and study visits were conducted in a private patient examination room. The
primary inclusion criterion was a resting BP, defined as the average of the last two of three
BP measurements taken by the research assistant using an automated device (BpTRU, VSM
Medtech, Model BPM-100), in the prehypertension range according to JNC 7 guidelines
(120-139/80-89 mm Hg). To limit the sample to newly identified prehypertension, potential
subjects were excluded if they reported ever having been informed of having elevated BP
(i.e., hypertension, high BP or prehypertension) by a physician or ever having been
prescribed antihypertensive medications. Those who reported a history of cardiovascular
disease, diabetes or kidney disease were also excluded. Eligible subjects who wished to
participate provided written informed consent and were scheduled for the baseline visit. The
study protocol was approved by the CUMC Institutional Review Board and the study was
conducted from July, 2009 through August, 2011.
Study Procedures
Baseline Visit—The research assistant measured the subject’s height and weight and
instrumented him/her with a Spacelabs 90207 ABP monitor (Spacelabs, Redmond, WA), a
validated oscillometric device. After fitting the subject with an appropriately sized cuff on
the non-dominant arm, the research assistant performed standard calibration procedures. As
described below, the average of three resting calibration measurements taken with the ABP
monitor served as the office BP measure used to calculate the white coat effect for each
study visit. The ABP monitors were programmed to collect and record (without display) BP
data every 30 minutes for 24 hours, after which time subjects used prepaid mailers to return
the equipment. Subjects also completed a battery of questionnaires at baseline, including
demographic data, medical history and health-related quality of life using the SF-12 measure
(33).
Randomization—Upon completion of the baseline visit, subjects were randomly assigned
to one of two groups: (1) Unlabeled, in which the physician informed them of their BP level
but did not give them a “prehypertension” label; or (2) Labeled, in which the physician
informed them of their BP level and discussed prehypertension with them. A statistician
determined group assignments using a computer-generated algorithm. The research
assistant, who remained blinded, provided one of the study physicians (three total) with the
top envelope from a stack of pre-prepared, sealed envelopes with the group assignment and
corresponding script. The scripts for both groups were developed in collaboration with
several physicians to be as realistic as possible with regard to length and content of
feedback.
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UNLABELED: “First, let me explain that a person’s blood pressure varies for a lot
of reasons, like drinking coffee or running around a lot or being stressed. Your
blood pressure today is in the high normal range, but we don’t pay much attention
to a single reading. We’ll measure your blood pressure again three months from
now to see how you’re doing.
LABELED: “First, let me explain that a person’s blood pressure varies for a lot of
reasons, like drinking coffee or running around a lot or being stressed. Your blood
pressure today is in what is called the ‘pre-hypertension’ range. This doesn’t mean
that you have hypertension, and you don’t need to take medication at this point.
However, it does mean that you are at increased risk for developing hypertension in
the future. Hypertension is a serious condition that can cause stroke, heart disease,
or kidney disease, and it must be treated. To prevent your blood pressure from
increasing to that level, there are things you can do, like losing weight, exercising
more, and eating less salt. If your blood pressure does increase in the future, I
might recommend that we consider treating you with anti-hypertension medication.
We’ll measure your blood pressure again three months from now, and if it’s still
high, we’ll discuss how to proceed.”
The decision to inform subjects in both groups of their BP may result in a smaller labeling
effect than if one group was provided no feedback at all. However, this control condition is
more consistent with a real clinical encounter in which patients are often told their BP level
when it is measured and given minimal feedback when it is below the threshold for
hypertension. The question addressed in this study was whether the prehypertension label
and accompanying risk information have an impact on patients above and beyond the
minimal feedback they typically receive.
3-Month Visit—Subjects were scheduled to complete a follow-up visit three months after
their baseline visit. At this time 24-hour ABPM and self-report questionnaires were repeated
to obtain follow-up measures of the white coat effect and health-related quality of life. A
brief questionnaire was also administered to assess diagnoses or treatments that may have
occurred since the baseline visit. Subjects were debriefed about the purpose of the study at
the end of the three-month visit, and those assigned to the Unlabeled group were given the
information the Labeled group previously received; individual feedback was tailored based
on current BP. Subjects received $50 compensation for completing each study visit for a
possible total of $100.
Statistical Analysis
Sample size calculations—Power calculations indicated that 45 subjects per group (90
total) would provide 93/90% power to detect group differences of 12/7 mm Hg in the
systolic/diastolic white coat effect, using two-tailed, α=.05 level F-tests. These estimates
were based on the experimental study of hypertension labeling conducted by Rostrup et al.
(29); given differences in the study designs, we reduced the expected effect sizes by 25%.
Standard deviations were estimated using previously collected longitudinal office BP and
ABP data (34). We recruited a sample of 100 to allow for attrition at follow-up and other
potential problems (e.g., insufficient ABP data) for 10% of subjects.
Outcome Variables—The primary study outcome was the white coat effect, computed as
the difference between office BP and the average daytime ABP (31). Office BP was defined
as the average of three resting BP measurements taken by the research assistant with the
ABP monitor during calibration at each study visit. This approach allows calculation of the
white coat effect using a measure of office BP that is obtained using the same device as the
ABP measure. The ABP measure was computed as the average of all awake readings during
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the monitoring period based on subject diaries; if sleep and wake times were not reported,
the daytime period was defined as 7AM to 10PM. The mean number of awake ABP
readings was 22.9 (SD=5.7) at baseline and 20.0 (SD=7.2) at three months.
The secondary outcome was health-related quality of life, assessed with the Short Form
(SF)-12, a validated and widely-used self-report measure (33). The SF-12 yields eight
subscales representing various domains of functioning, which are combined to create
Physical Component Summary (PCS) and Mental Component Summary (MCS) measures.
Each subscale contributes to both summary measures, but physical functioning, physical role
limitation, bodily pain and general health are weighted more heavily in the PCS score, while
mental health, emotional role limitation, social function and vitality are weighted more
heavily in the MCS score. PCS and MCS scores are transformed based on U.S. normative
data to a mean of 50 and standard deviation of 10, where higher scores reflect better
functioning.
Analysis Plan—Descriptive statistics were used to characterize the sample and test for any
group differences at baseline. Linear multilevel repeated-measures regression analyses were
performed to generate full-information maximum-likelihood estimates of labeling effects on
the changes the white coat effect, separate office BP and ABP measures, and health-related
quality of life from baseline to three months (Group X Time interactions). Following the
primary analyses, we examined the effects of prehypertension labeling on each of the
outcome measures after adjusting for a set of relevant covariates (age, sex, race/ethnicity,
body mass index). Analyses were performed using SPSS v.20.
RESULTS
Figure 1 shows the study flowchart. Of the 100 subjects who were enrolled and randomized,
71 completed the three-month follow-up visit; the dropout rate did not differ by group
(χ2=0.44, df=1, P=0.51). Inability to recontact subjects was the primary reason for loss to
follow-up, and several subjects moved or withdrew from the study. There were no
significant differences between subjects who dropped out and those who completed the
study with regard to demographic characteristics (age, sex, race/ethnicity; Ps>0.75), the
white coat effect (Ps>0.20), office BP (Ps>0.77), daytime systolic BP (P=0.36), or health-
related quality of life (Ps>0.60); however, subjects who dropped out had higher body mass
index (29.3 kg/m2 vs. 25.7 kg/m2, P=0.02) and lower daytime diastolic BP (76.1 mm Hg vs.
79.1 mm Hg, P=0.04) compared with those who completed the study.
Sample characteristics
The enrolled sample was racially and ethnically diverse, with 42% Hispanic subjects, 36%
non-Hispanic whites, 12% non-Hispanic blacks, 7% Asian and 3% other races. The age
range was 19 to 82 years with a mean of 40.0 years (SD=14.3), and 54% of subjects were
women. As shown in Table 1, demographic characteristics of the two experimental groups
were similar. There were no significant group differences at baseline in office BP, the white
coat effect or mental health, but subjects in the Labeled group reported better physical health
than those in the Unlabeled group (PCS = 50.5 vs. 47.8, P=0.02) and had somewhat higher
average daytime diastolic BP (79.5 mm Hg vs. 77.0 mm Hg, P=0.06).
Effects of prehypertension labeling
Results of the primary intent-to-treat analysis of change in the white coat effect from
baseline to three months are presented in Table 2. Although the use of mixed effects
regression allows inclusion of subjects with missing follow-up data, three subjects who
dropped out were not included in this analysis because missing BP data prevented
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calculation of a baseline white coat effect. On average, the systolic white coat effect
increased by 2.2 mm Hg in the Labeled group and decreased by 1.0 mm Hg in the Unlabeled
group, while the diastolic white coat effect was essentially unchanged in both groups; as
shown in Table 2, the Group X Time interaction was not statistically significant for either
outcome (Ps>0.30). There were also no significant differences in the effects of
prehypertension labeling on the separate measures of office BP (Ps>0.48) or mean daytime
ABP (Ps>0.39).
For descriptive purposes, we also examined changes in BP classification by study group. By
design, all subjects were prehypertensive at baseline; the majority of subjects in both groups
continued be classified as prehypertensive at the three-month follow-up based on office BP
(58.8% Labeled, 54.5% Unlabeled). A higher proportion of Labeled versus Unlabeled
subjects were classified as hypertensive at follow-up (17.6% Labeled, 12.1% Unlabeled) and
fewer Labeled subjects were classified as normotensive (23.5% Labeled, 33.3% Unlabeled).
However, consistent with the results based on continuous BP measures, group differences in
office BP classification at follow-up were not statistically significant (χ2= 0.96, df=2,
P=0.62). There was also no significant difference in the proportion of Labeled and
Unlabeled subjects who met criteria for white coat hypertension at three months (P=0.49).
Next, we tested the effects of prehypertension labeling on health-related quality of life. One
subject who dropped out of the study had missing SF-12 data at baseline and thus was not
included in these analyses. Results of this set of mixed effects regression analyses indicated
that prehypertension labeling did not significantly influence self-reported physical or mental
health. The average PCS score decreased by 1.7 in the Labeled group and by 0.6 in the
Unlabeled group (P=0.24 for the Group X Time interaction), and the average MCS score
decreased by 0.2 in the Labeled group and increased by 2.1 in the Unlabeled group (P=0.34
for the Group X Time interaction).
As shown in Table 2, the magnitude and significance level of the effects of labeling on each
of the outcomes did not change substantially when we adjusted for age, sex, race/ethnicity
and body mass index. The follow-up questionnaire indicated that none of the subjects began
taking antihypertensive medication between the baseline and three-month visits. However,
at the three-month visit, two subjects (one in each group) reported that they had in fact had
high BP diagnosed and/or treated prior to enrolling in the study. Repeating the primary
analyses without these two subjects revealed no change in the significance of any of the
findings. Although we did not power the study to detect interactions, we were also interested
in exploring whether the effects of prehypertension labeling differed by race/ethnicity, given
our previous work demonstrating race differences in the effects of hypertension awareness
(23). The Group X Time X Race/ethnicity (non-Hispanic white vs. minority) interaction was
not statistically significant for the systolic or diastolic white coat effect (Ps>0.30), office BP
(Ps>0.77), mean daytime ABP (Ps>0.68) or physical or mental health (Ps>0.49), indicating
that prehypertension labeling had minimal effects among both white and minority
participants.
DISCUSSION
The detection of prehypertension is intended to improve patients’ health outcomes by
delaying the onset of hypertension. However, evidence of the negative effects of
hypertension labeling has led to questions regarding the potential consequences of labeling
patients at even lower BP levels (35). Contrary to our hypothesis, results of this randomized,
controlled study suggest that prehypertension labeling does not negatively affect patients.
Specifically, labeling did not lead to increases in the white coat effect, office BP or ABP,
and there were no differences in the proportion of Labeled and Unlabeled prehypertensive
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participants who met criteria for white coat hypertension at three months. Changes in self-
reported physical and mental health also did not differ between the groups. These findings
suggest that the potential benefits of early identification of prehypertension are unlikely to
be limited by unintended consequences of labeling patients.
Only one other published study has investigated the effects of prehypertension labeling.
Using a similar design, Viera et al. (36) randomly assigned newly identified prehypertensive
patients to labeled or unlabeled groups and examined changes in perceived health and
adoption of recommended lifestyle modifications three months later. They found no
differences between the groups with regard to self-reported changes in exercise or dietary
behaviors, and consistent with our findings, there was no evidence that prehypertension
labeling adversely affected patients’ perceived health. Thus, the previously reported
negative effects of hypertension awareness on health-related quality of life (23–28) do not
appear to extend to prehypertension. Whether this discrepancy reflects the perceived
severity of a hypertension diagnosis, patients’ feelings about the need for drug treatment,
differences in patient-physician communication, or some combination, is unknown.
To our knowledge, ours is the first study to examine effects of prehypertension labeling on
BP. Rostrup et al. (29,30) found significant increases in office BP among labeled versus
unlabeled hypertensive subjects, although ABPM was not performed so changes in the white
coat effect could not be assessed. Still, effects of labeling on office BP were much smaller in
our study. In addition to the significance of the label itself (i.e., hypertension vs.
prehypertension), differences in the study designs may have contributed to this discrepancy.
The present study involved a more active comparison condition, and subjects were assessed
three months after being labeled, compared with two weeks in the Rostrup study. On the
other hand, labeling was performed in-person by a physician in the present study rather than
via mailed letters in the Rostrup study. Again, it is also likely that subjects’ health beliefs
and level of knowledge about prehypertension played a role. How patients interpret
diagnostic and risk information is an important question for future research that may help to
explain behavioral and psychological responses to labeling.
The present study is one of the few experimental investigations of either prehypertension or
hypertension labeling that have been conducted to date. This is an important strength,
however labeling is a complicated phenomenon to study and there is no ideal design. While
the use of scripted physician messages was important for experimental control, the feedback
physicians provide in the real world may differ in meaningful ways. Also, the fact that
subjects in both groups received some feedback about their BP may have resulted in a
smaller labeling effect than if one group was provided no feedback at all. This design
reflects the primary aim of the study, which was to determine whether being labeled as
prehypertensive by a physician and informed of the associated health risks would have a
greater effect on subjects than the minimal level of feedback they would likely receive in
usual clinical care.
Several other limitations must be noted. First, the follow-up period was relatively short, and
it is possible that effects of labeling may emerge later. We chose three months because this
is a typical follow-up interval for monitoring BP in this range in primary care settings, and
because of ethical concerns regarding withholding diagnostic information for longer than
three months. Second, although the dropout rate did not differ by group, it is possible that
subjects who did not return for the follow-up visit were those who were most affected by the
feedback (either version), thereby underestimating the effects of labeling. Finally, we could
not verify that subjects had never been informed of having high BP prior to enrolling in the
study. Two subjects indicated a previous history of labeling after being enrolled and there
may have been others who did not report this to us.
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Results of the current study indicate that labeling patients with prehypertension does not
negatively affect their BP or quality of life, at least in the short-term. Given that more than
one-third of U.S. adults have prehypertension, the potential impact of targeting prevention
efforts among this group is substantial. Prehypertension is associated with a low prevalence
of healthy lifestyle behaviors (37), and positive effects of lifestyle modification among this
group have been demonstrated (38–40). However, little is currently known about how often
physicians use the prehypertension classification when treating patients (41), and how
patients recall and respond to this information. Recent findings indicate that labeling patients
with prehypertension does not increase lifestyle modification (36), suggesting that while
using this classification may not be harmful to patients, it is also not particularly helpful.
Additional research is needed to determine approaches to communicating with patients
about their BP that will increase the likelihood of behavior change and lead to improved
health outcomes.
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Table 1
Baseline characteristics by group
Unlabeled (N=50) Labeled (N=50) P*
Age, years 39.7 (16.4) 40.2 (12.1) 0.84
Sex, % (N) female 60.0% (30) 48.0% (24) 0.23
Race/ethnicity, % (N) minorities 66.0% (33) 62.0% (31) 0.68
BMI, kg/m2 26.9 (5.8) 26.5 (5.5) 0.73
White coat effect, systolic, mm Hg 3.6 (10.4) 2.0 (9.7) 0.44
White coat effect, diastolic, mm Hg 2.0 (9.4) 1.0 (8.4) 0.56
Office BP, systolic, mm Hg 126.7 (12.1) 126.0 (12.5) 0.76
Office BP, diastolic, mm Hg 79.1 (8.2) 80.7 (9.3) 0.37
Mean daytime ABP, systolic, mm Hg 123.0 (7.5) 124.2 (9.3) 0.46
Mean daytime ABP, diastolic, mm Hg 77.0 (6.8) 79.5 (6.1) 0.06
Physical health (SF-12, PCS) 47.8 (6.9) 50.5 (3.6) 0.02
Mental health (SF-12, MCS) 46.3 (9.2) 46.9 (6.1) 0.69
Note: Data are presented as mean (SD) unless otherwise indicated.
*
Based on independent-sample t test for continuous variables and χ2 test for categorical variables.
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